Clinical trials
Alzheimer Disease or Associated Disorder clinical trials
Below are recruiting alzheimer disease or associated disorder clinical trials, each written for real people, not researchers. We’re tracking 1,805 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06582199Recruiting
Personalized Alzheimer's study using brain scans and spinal fluid
This study looks at how to better predict and understand Alzheimer's disease by using advanced brain scans and spinal fluid tests. It aims to find ways to identify people who stay healthy longer despite risk factors.
ParisAges 50–90 - NCT06582706RecruitingPhase 1/Phase 2
Vitamin B3 (niacin) for Alzheimer's disease
This study tests if nicotinic acid (a form of vitamin B3) can help people with mild to moderate Alzheimer's disease. It involves taking a daily pill, having a lumbar puncture, and regular check-ups to see if the vitamin improves thinking and memory.
Indianapolis, IndianaAges 60–85 - NCT06566170Recruiting
Donanemab for early Alzheimer's: a real-world study
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
Huntsville, AlabamaAges 60 years+ - NCT06538311RecruitingEarly Phase 1
TMS treatment for early Alzheimer's disease
This study tests whether a non-invasive brain stimulation treatment called TMS (transcranial magnetic stimulation) can help people with early Alzheimer's disease or related memory problems. It's a safe, gentle way to stimulate brain cells using magnetic pulses.
Boston, MassachusettsAges 40–99 - NCT06514001RecruitingPhase 2
Testing a new drug for Alzheimer's disease with eye scans
This trial tests an investigational drug called AMDX-2011P for people with Alzheimer's disease. It looks at whether the drug affects the retina, which may be linked to brain changes in Alzheimer's.
Phoenix, ArizonaAges 18 years+ - NCT06511752RecruitingEarly Phase 1
Support group for Spanish/English speakers with progressive aphasia
This trial tests a support group program for people with progressive aphasia (a language disorder that gets worse over time) and their caregivers. The groups meet online to share experiences and learn together.
Austin, TexasAges 18 years+ - NCT06481878Recruiting
Testing a stool test for Alzheimer’s markers
This study checks if Alzheimer’s-related proteins (amyloid and tau) can be found in stool samples. It may help develop a simple, non-invasive way to detect Alzheimer’s disease.
GrenobleAges 40 years+ - NCT06484244Recruiting
Walking and balance in memory loss
This study looks at how older adults with mild cognitive impairment or Alzheimer's disease adapt their walking. It aims to understand walking and balance to help people stay mobile and safe longer.
Atlanta, GeorgiaAges 50–90 - NCT06439992Recruiting
New PET scan tracer to detect Alzheimer's in the brain
This study tests a new PET imaging tracer called Fluselenamyl to see how well it shows amyloid plaques (a protein linked to Alzheimer's) in the brain. It may help improve early diagnosis for people with Alzheimer's or support research in healthy volunteers.
St Louis, MissouriAges 18 years+ - NCT06362707RecruitingPhase 2
Fasudil trial for early Alzheimer's disease
This trial tests a medication called fasudil to see if it can help people with early Alzheimer's disease. It is for people who have early symptoms (mild cognitive impairment or mild dementia) and have biomarker evidence of Alzheimer's in their brain.
Tromsø, NordlandAges 50–100 - NCT06374875RecruitingPhase 4
Does metabolic surgery reduce liver scarring?
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
Phoenix, ArizonaAges 18–75 - NCT06322667Recruiting
Study of lecanemab in early Alzheimer's disease
This study tracks the real-world experience of people with early Alzheimer's disease who are already taking lecanemab. It aims to better understand how the medication works and its safety in everyday medical practice.
HiroshimaAges 18 years+ - NCT06297590RecruitingPhase 1
First human study of a new Alzheimer's drug
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
Maitland, FloridaAges 50–85 - NCT06313944Recruiting
German registry of Alzheimer's treated with sound wave therapy
This trial is a registry that collects information about people with Alzheimer's disease who receive a treatment called transcranial pulse stimulation (TPS), which uses gentle sound waves to stimulate the brain. The goal is to track safety and how well it works over time.
Potsdam, BrandenburgAges 18–85 - NCT06274528RecruitingPhase 2
DORA and lemborexant in Alzheimer's biomarkers study
This study is testing whether a sleep medication called lemborexant can improve sleep and reduce Alzheimer's-related proteins in healthy older adults with no memory problems. It could help find new ways to delay or prevent Alzheimer's disease.
St Louis, MissouriAges 65 years+ - NCT06189963RecruitingPhase 1/Phase 2
Cell therapy trial for moderate Alzheimer's disease
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
Glendale, CaliforniaAges 40–85 - NCT06194799Enrolling by invitationPhase 3
Long-term ACP-204 for Alzheimer's psychosis
This study tests a long-term medicine (ACP-204) for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). If you took part in the earlier ACP-204 study, this open-label extension lets you continue receiving the medicine to see how well it works over time.
Costa Mesa, CaliforniaAges 55–95 - NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Chandler, ArizonaAges 55–95 - NCT06129838Recruiting
Inflammation in Alzheimer's disease using a brain scan
This study uses a special PET scan to look for inflammation in the brains of people with Alzheimer's or related dementias. It may help researchers understand how inflammation affects memory and thinking problems.
St Louis, MissouriAges 50 years+ - NCT06099587Recruiting
Brain scan study for early Alzheimer's memory changes
This study uses a special MRI scan to look at the brain's memory center in people with early memory concerns. It aims to better understand changes that happen in the very early stages of Alzheimer's disease.
RennesAges 50–80 - NCT06094192Recruiting
Brain stimulation to improve memory in Alzheimer's
This study tests whether a gentle, noninvasive brain stimulation technique called tACS can help improve memory in people with Alzheimer's disease or mild cognitive impairment. It may also include healthy older adults for comparison.
Boston, MassachusettsAges 50–100 - NCT06078891Enrolling by invitationEarly Phase 1
BCG vaccine to lower Alzheimer's blood markers
This trial tests whether the BCG vaccine (a tuberculosis vaccine) can lower a blood marker linked to Alzheimer's disease. It is for people aged 70–80 who have slightly elevated p-tau181 levels but still have normal thinking and daily living skills.
JerusalemAges 70–80 - NCT06052163RecruitingPhase 2
Testing bumetanide for early Alzheimer's disease
This study tests whether a water pill called bumetanide can help people with early Alzheimer's disease. It involves taking the study drug, having MRI scans, and doing memory tests to see if it slows down symptoms.
Stanford, CaliforniaAges 50–85 - NCT06023446Enrolling by invitation
Can eye photos detect early Alzheimer's disease?
This study uses a special camera (OCT) to take pictures of the retina (the back of your eye) to see if it can detect Alzheimer's disease very early. You may be eligible if you are either cognitively normal or have mild cognitive impairment, and have already had a test for Alzheimer's-related brain changes.
Sacramento, CaliforniaAges 50–89
Hear when a new Alzheimer Disease or Associated Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer disease or associated disorder?
- Yes. Clin2 currently lists 1,805 recruiting alzheimer disease or associated disorder studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer disease or associated disorder trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer disease or associated disorder trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.